Dr. Ed Esplin is a physician scientist board certified in clinical genetics and internal medicine with a focus on using comprehensive germline and solid-tumor somatic genomic information to provide patients with cancer, cardiomyopathy, epilepsy and other rare diseases access to precision therapies and access to clinical trials to improve care for patients, and genomic screening to identify modifiable genetic disease risks in healthy individuals. Medical Officer at Invitae for 10 years, he currently leads clinical trials and research at Labcorp Genetics (formerly Invitae) including the INTERCEPT trial with Dr. Jewel Samadder at the Mayo Clinic; the PROCLAIM trial in prostate cancer with Dr. Neal Shore; the Universal Germline Testing in the Community trial (UNITY, NCT05416710) with Dr. Kashyap Patel; and Labcorp Genetics collaboration with the eMERGE IV Consortium evaluating the clinical utility of genomic screening in healthy individuals. Dr. Esplin completed the MSTP program at UT Southwestern obtaining his MD and PhD in genetics, completed internal medicine residency training and served as an Assistant Professor of Internal Medicine at UT Southwestern. He subsequently completed clinical genetics training at Stanford University followed by an NIH-funded Tashia and John Morgridge Endowed Postdoctoral Fellowship with Mike Snyder in the Stanford Department of Genetics, where he maintains an academic appointment and is a consulting investigator for the Stanford Pre-Cancer Atlas as part of the NIH Human Tumor Atlas Network (HTAN). He serves on the ACMG Therapeutics Committee and is a fellow of the American College of Medical Genetics and Genomics (ACMG), the Collaborative Group of the Americas for Inherited Gastrointestinal Cancer (CGA-IGC) and the American College of Physicians (ACP).